Novacyt SA shares extended their year-to-date surge to more than 1,600% after the company’s Covid-19 test was listed as eligible for procurement by the World Health Organization.
The stock jumped as much as 22% on the Euronext Growth market in Paris as Novacyt said its diagnostics kit would be available for a year following an emergency process by WHO. The company has a market capitalization of 197 million euros ($214 million).
